Clinical Trial Update: GIC-102, Intravenous Allogeneic NK Cells, in Subjects With Advanced Solid Cancers and R/R Hematologic Malignancies [Phase 1, Phase 2]

View source ↗

Summary

GIC-102, an intravenously administered allogeneic NK cell therapy, is being evaluated in Phase 1/Phase 2 trials for advanced solid tumors and relapsed/refractor…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma
• Non-hodgkin Lymphoma
• Solid Tumors

Drugs mentioned

• GIC-102

Snippet

Sponsor: GI Cell, Inc. | Conditions: Advanced Solid Tumors, Relapsed/Refractory Non-Hodgkin Lymphoma | Phase 1, Phase 2 | Status: RECRUITING